doxorubicin-CEA conjugate (Immunomedics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namedoxorubicin-CEA conjugate (Immunomedics)

Drug Alias NameDOX-CEA

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionTopoisomerase II inhibitorsCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsTopoisomerase IICarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A